272 related articles for article (PubMed ID: 15857674)
1. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
[TBL] [Abstract][Full Text] [Related]
2. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
[TBL] [Abstract][Full Text] [Related]
3. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
[TBL] [Abstract][Full Text] [Related]
4. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
[TBL] [Abstract][Full Text] [Related]
5. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical localization of aspartoacylase in the rat central nervous system.
Madhavarao CN; Moffett JR; Moore RA; Viola RE; Namboodiri MA; Jacobowitz DM
J Comp Neurol; 2004 May; 472(3):318-29. PubMed ID: 15065127
[TBL] [Abstract][Full Text] [Related]
7. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain.
Janson C; McPhee S; Bilaniuk L; Haselgrove J; Testaiuti M; Freese A; Wang DJ; Shera D; Hurh P; Rupin J; Saslow E; Goldfarb O; Goldberg M; Larijani G; Sharrar W; Liouterman L; Camp A; Kolodny E; Samulski J; Leone P
Hum Gene Ther; 2002 Jul; 13(11):1391-412. PubMed ID: 12162821
[TBL] [Abstract][Full Text] [Related]
8. Canavan disease: a white matter disorder.
Kumar S; Mattan NS; de Vellis J
Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907
[TBL] [Abstract][Full Text] [Related]
9. Involvement of aspartoacylase in tremor expression in rats.
Nishitani A; Tanaka M; Shimizu S; Kunisawa N; Yokoe M; Yoshida Y; Suzuki T; Sakuma T; Yamamoto T; Kuwamura M; Takenaka S; Ohno Y; Kuramoto T
Exp Anim; 2016 Jul; 65(3):293-301. PubMed ID: 27026062
[TBL] [Abstract][Full Text] [Related]
10. Adenoviral gene transfer of aspartoacylase ameliorates tonic convulsions of spontaneously epileptic rats.
Seki T; Matsubayashi H; Amano T; Kitada K; Serikawa T; Sasa M; Sakai N
Neurochem Int; 2004 Jul; 45(1):171-8. PubMed ID: 15082234
[TBL] [Abstract][Full Text] [Related]
11. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
[TBL] [Abstract][Full Text] [Related]
12. Canavan disease and the role of N-acetylaspartate in myelin synthesis.
Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN
Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of N-acetylaspartic acid resulting nitric oxide toxicity induces aspartoacylase mutations and protein interaction to cause pathophysiology seen in Canavan disease.
Surendran S
Med Hypotheses; 2010 Dec; 75(6):533-4. PubMed ID: 20673702
[TBL] [Abstract][Full Text] [Related]
14. Endogenous aspartoacylase expression is responsive to glutamatergic activity in vitro and in vivo.
Francis JS; Strande L; Pu A; Leone P
Glia; 2011 Oct; 59(10):1435-46. PubMed ID: 21608034
[TBL] [Abstract][Full Text] [Related]
15. Adenoviral gene transfer of aspartoacylase into the tremor rat, a genetic model of epilepsy, as a trial of gene therapy for inherited epileptic disorder.
Seki T; Matsubayashi H; Amano T; Kitada K; Serikawa T; Sakai N; Sasa M
Neurosci Lett; 2002 Aug; 328(3):249-52. PubMed ID: 12147318
[TBL] [Abstract][Full Text] [Related]
16. Aspartoacylase is a regulated nuclear-cytoplasmic enzyme.
Hershfield JR; Madhavarao CN; Moffett JR; Benjamins JA; Garbern JY; Namboodiri A
FASEB J; 2006 Oct; 20(12):2139-41. PubMed ID: 16935940
[TBL] [Abstract][Full Text] [Related]
17. Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease.
Arun P; Madhavarao CN; Moffett JR; Hamilton K; Grunberg NE; Ariyannur PS; Gahl WA; Anikster Y; Mog S; Hallows WC; Denu JM; Namboodiri AM
J Inherit Metab Dis; 2010 Jun; 33(3):195-210. PubMed ID: 20464498
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective adeno-associated virus Bcl-xL gene transfer in models of motor neuron disease.
Garrity-Moses ME; Teng Q; Liu J; Tanase D; Boulis NM
Muscle Nerve; 2005 Dec; 32(6):734-44. PubMed ID: 16116646
[TBL] [Abstract][Full Text] [Related]
19. Favorable effects of VEGF gene transfer on a rat model of Parkinson disease using adeno-associated viral vectors.
Tian YY; Tang CJ; Wang JN; Feng Y; Chen XW; Wang L; Qiao X; Sun SG
Neurosci Lett; 2007 Jun; 421(3):239-44. PubMed ID: 17574749
[TBL] [Abstract][Full Text] [Related]
20. Expression of aspartoacylase (ASPA) and Canavan disease.
Sommer A; Sass JO
Gene; 2012 Sep; 505(2):206-10. PubMed ID: 22750302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
